cadorex 300 mg/ml
livisto int’l, s.l., av. universitat autònoma, 29, 08290 cerdanyola del vallès (barcelona), Španjolska - florfenikol - otopina za injekciju - antibakterijski lijekovi za sustavne infekcije - goveda, ovaca, svinja
xtandi
astellas pharma europe b.v. - enzalutamide - prostatske neoplazme - endokrinska terapija - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
csc 14 kardioplegijski izmjenjivaČ topline i vanguard kardioplegijski set
boston medical d.o.o., zagreb - digitalni kardioplegijski izmjenjivač topline
lynparza
astrazeneca ab - olaparib - neoplazme jajnika - antineoplastična sredstva - jajnika cancerlynparza prikazan kao monoterapija za:podržava liječenje odraslih bolesnika s поздними (figo faze iii i iv) u genima brca1/2-mutirani (зародышевой linije i/ili somatskih) brzorezni epitela jajnika, masterbatch cijevi ili primarni перитонеальный rak, koji u odgovor (potpuno ili djelomično) nakon završetka prve linije na bazi platine kemoterapije. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 i 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. pacijenti moraju prethodno bile tretirane s антрациклина i таксана u (neo)adjuvantne ili метастатический, ako pacijenti nisu prikladni za tih postupaka (vidi odjeljak 5. pacijenti s receptore hormona (h)-pozitivnog raka dojke treba također razvili ili nakon pre-hormonska terapija, ili se smatraju neprikladnim za endokrine terapije. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.
ozurdex
abbvie deutschland gmbh & co. kg - deksametazon - macular edema; uveitis - ophthalmologicals, other ophthalmologicals - Озурдекс indiciran za liječenje odraslih bolesnika s макулярным oticanjem nakon odvajanja mrežnice beča окклюзия (brvo) ili središnje vene mrežnice окклюзия (crvo). Озурдекс indiciran za liječenje odraslih bolesnika s upala stražnjeg segmenta oka, predstavljajući kao неинфекционный uveitis. Озурдекс indiciran za liječenje odraslih bolesnika s oštećenjem vida zbog dijabetes pomagala макулярного edema (ДМО), koji артифакии ili koga smatraju da je nedovoljno fleksibilan ili neprikladan za nepušače кортикостероидной terapija.
nubeqa
bayer ag - darolutamide - tumori prostate, Кастраци-uporan - endokrinska terapija - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.
erleada
janssen-cilag international nv - apalutamide - prostatske neoplazme - endokrinska terapija - erleada drugačije:kod odraslih muškaraca u liječenju ne metastatic кастраци-uporan je rak prostate (nmcrpc), koje imaju visok rizik za razvoj bolesti метастатической. kod odraslih muškaraca u liječenju метастатического hormonski-senzitivni rak prostate (mhspc) u kombinaciji s terapijom oduzimanja андрогена (adt).
abirateron alpha-medical 500 mg filmom obložene tablete
alpha-medical d.o.o., dragutina golika 36, zagreb, hrvatska - abirateronacetat - filmom obložena tableta - urbroj: svaka tableta sadrži 500 mg abirateronacetata
abirateron sandoz 1000 mg filmom obložene tablete
sandoz d.o.o., maksimirska 120, zagreb, hrvatska - abirateronacetat - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 1000 mg abirateronacetata
abirateron sandoz 250 mg filmom obložene tablete
sandoz d.o.o., maksimirska 120, zagreb, hrvatska - abirateronacetat - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 250 mg abirateronacetata